^
CANCER:

Colon Cancer





Show legend
Group by Gene:
Include preclinical:

bevacizumab
bevacizumab-adcd
0
VEGF-A inhibitor
bevacizumab-awwb
bevacizumab-maly
bevacizumab-bvzr
1
HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
fam-trastuzumab deruxtecan-nxki
cetuximab
2
EGFR inhibitor
panitumumab
ABP 494 (cetuximab biosimilar)
dostarlimab-gxly
pembrolizumab
3
PD1 inhibitor
sintilimab
nivolumab
tislelizumab
4
VEGFR inhibitor
fruquintinib
5
Multi-tyrosine kinase inhibitor
regorafenib
anlotinib
panitumumab + adagrasib
6
KRAS G12C inhibitor, EGFR inhibitor
panitumumab + sotorasib
cetuximab + sotorasib
cetuximab + adagrasib
7
Topoisomerase I inhibitor
irinotecan
8
Thymidylate synthase inhibitor, Topoisomerase I inhibitor
5-fluorouracil + irinotecan
9
HER2 inhibitor, HER2 dimerization inhibitor
trastuzumab + pertuzumab
10
Thymidylate synthase inhibitor
capecitabine
5-fluorouracil
11
HER2 inhibitor
trastuzumab + tucatinib
12
DNA synthesis inhibitor, DNA cross linking agent
oxaliplatin
13
VEGFR-2 inhibitor
ramucirumab
14
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
15
TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
larotrectinib
16
FGFR inhibitor
Debio 1347
17
PARP inhibitor
olaparib
talazoparib
18
RET inhibitor
selpercatinib
pralsetinib
19
ALK inhibitor, Multi-tyrosine kinase inhibitor
crizotinib + pazopanib
20
Immunotherapy
Immunotherapy
CAPOX
FOLFOX
mFOLFOX6
21
Chemotherapy
FLOX
FOLFIRINOX
IROX
mFOLFOX7
FOLFIRI
22
CDK9 inhibitor
CDK9 inhibitor
KB-0742
23
DNA synthesis inhibitor, DNA cross linking agent, Folate analog, Thymidylate synthase inhibitor
5-fluorouracil + oxaliplatin + leucovorin calcium
24
HER2 inhibitor, EGFR inhibitor
trastuzumab + lapatinib
lapatinib
25
Folate analog, Thymidylate synthase inhibitor
5-fluorouracil + leucovorin calcium
26
VEGF-A inhibitor, VEGF-B inhibitor, PIGF inhibitor, Chemotherapy
FOLFIRI + ziv-aflibercept IV
27
cRAF inhibitor, BRAF inhibitor, EGFR inhibitor
panitumumab + encorafenib
cetuximab + encorafenib
28
TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
entrectinib
29
HER2-targeted antibody-drug conjugate, Microtubule inhibitor
ado-trastuzumab emtansine
30
pan-RAF inhibitor, EGFR inhibitor, Multi-tyrosine kinase inhibitor
cetuximab + sorafenib
31
VEGF-A inhibitor, PD1 inhibitor
bevacizumab + sintilimab
32
BRAF inhibitor, EGFR inhibitor, BRAF V600E inhibitor
cetuximab + vemurafenib
33
Trk inhibitor
FCN-098
34
MEK inhibitor
binimetinib
trametinib
35
PI3K inhibitor
AN2025
36
BCAT1 inhibitor
ERG 245
37
DNA synthesis inhibitor
cisplatin
38
E3 ubiquitin-ligase hakai inhibitor
Hakin-1
39
Tubulin polymerization promoter, Bcl2 inhibitor
paclitaxel
40
PD-L1 inhibitor, IL-15R stimulant
SAR445710
41
Chk1 inhibitor
LY 2603618
42
Microtubule stabilizer, Tubulin polymerization promoter
docetaxel
43
CD137 agonist, PD1 inhibitor
Opal
44
Bcr-abl tyrosine kinase inhibitor, EGFR inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
cetuximab + dasatinib
45
c-MET inhibitor, RON inhibitor, TrkA receptor inhibitor, Aurora kinase A inhibitor, FLT3 inhibitor
KRC-108
46
AMPK activator, Selective serotonin reuptake inhibitor
metformin + fluoxetine
47
CLDN18.2-targeted antibody-drug conjugate, DNA replication inhibitor
SOT102
48
TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
DS-1062a
49
PD-L1 inhibitor, CD47 inhibitor
NI-2901
50
HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor, WEE1 inhibitor
fam-trastuzumab deruxtecan-nxki + AZD1775
51
Cripto-targeted antibody-drug conjugate, Microtubule inhibitor
BIIB015
52
LAMP1-targeted antibody-drug conjugate, Microtubule inhibitor
SAR428926
53
VEGFR-2 inhibitor, c-KIT inhibitor
OSI-930
54
BRAF inhibitor, BRAF V600E inhibitor
vemurafenib
55
MEK inhibitor, PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
PF-05212384 + PD-0325901
56
TLR5 agonist, CD133-targeted CAR-T immunotherapy, Apoptosis inhibitor
CD133-specific CAR-T cell therapy + STAT-600
57
PD-L1 inhibitor
CCX559
58
MEK inhibitor, BRAF inhibitor
trametinib + dabrafenib
59
β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
eribulin mesylate
60
PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
PF-05212384
CS-1018
61
STING agonist
CS-1010
CS-1020
62
BRAF inhibitor
ABM-1310
No biomarker
KRAS G12C
KRAS wild-type
MSI-H/dMMR + KRAS G12D
KRAS mutation
KRAS G12R
KRAS N116H
KRAS N116T
KRAS Q22X
KRAS G13D
KRAS G12V
HER-2 amplification + RAS wild-type + BRAF wild-type
BRAF V600E
RAS wild-type + BRAF wild-type
BRAF mutation
BRAF wild-type
BRAF V600
MSI-H/dMMR
miR-31-5p underexpression
POLE A456P
MSI-H/dMMR + POLE P286R
POLE V411L
ATM mutation
RET fusion
NTRK3 fusion
MSI-H/dMMR + TMB-H + POLE mutation
POLE P286R + TMB-H
RAF1 R256S
NTRK2 fusion
BRCA2 mutation
PMS2 negative
TERT mutation + ERBB4 mutation
TMB-H
BRIP1 mutation
ATR mutation
AEBP1 expression
KRAS wild-type + NRAS wild-type + MSI-H/dMMR
BGN expression
MSH2 489_494deTGGGTA
TAGLN expression
NTRK1 fusion
MSI-H/dMMR + KRAS wild-type + BRAF wild-type
TET1 mutation
NRAS wild-type
HER-2 positive
RAD50 mutation
FGFR2-INA fusion
FGFR2 fusion
ALK R1209Q
HER-2 expression
ROS1 amplification
CLDN18.2 expression
PD-1 positive
TROP2 expression
KRAS mutation + TP53 wild-type
PD-L1 expression + CD47 expression
ETV5 overexpression
MAP2K1 K57T
SIRT6 underexpression
AREG expression
FGFR4 expression
RAS wild-type
APC mutation
CRIPTO expression
LAMP1 expression
MAP2K1 V211D
TPM3-NTRK1 G595R
ETV6-NTRK3 G623R
PIK3CA H1047R
TP53 mutation
SMAD4 mutation
ABCB1 expression
NR4A1 overexpression
EGFR G719S
EZR overexpression + BRAF V600E
CD133 expression
PIK3CA mutation
ARID1A deletion
miR-375 expression
miR-199a-5p expression
MLH1 deletion
PD-L1 expression
TERT mutation + BRAF V600E
EGFR G724S
CIC deletion
STING mutation
LMNA-NTRK1 G667C
EGFR E709K
EGFR L858R
EGFR P596L
EGFR R222C
EGFR R165Q
EGFR E114K
EGFR G63R
EGFR K708R
BCAT1 expression
KLF4 overexpression
CDH1 expression
FBXW7 overexpression
PD-L1 negative
TP53 mutation + KRAS mutation
MYC amplification